Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies
- 572 Downloads
Despite the widespread use of rituximab, a chimeric monoclonal antibody with demonstrated efficacy in the treatment of non-Hodgkin’s lymphomas, there is a recognized need to develop new agents with improved efficacy. Towards this end, using XenoMouse® technology, a fully human IgG1 anti-CD20 monoclonal antibody was generated. This antibody, denoted mAb 1.5.3, evoked enhanced pro-apoptotic activity in vitro, as compared to rituximab, in the Ramos lymphoma cell line. Also, mAb 1.5.3 mediated both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) similar to rituximab in human B-lymphoma lines. Interestingly, mAb 1.5.3 demonstrated superior ADCC compared to rituiximab when FcγRIIIa F/F allotype donors were profiled and superior cytolytic activity across multiple human B-lymphoma and chronic B-cell leukemia lines in an in vitro whole blood assay. Furthermore, mAb 1.5.3 exhibited enhanced anti-tumor activity in Ramos, Daudi, and Namalwa tumour xenograft models. Lastly, mAb 1.5.3 produced a superior B-cell depletion profile in lymph node organs and bone marrow as compared to rituximab in a primate pharmacodynamic (PD) model. These findings underscore the potential of mAb 1.5.3 to exhibit improved clinical activity in the treatment of B-cell malignancies compared to rituximab.
KeywordsCD20 Antibody ADCC CDC Apoptosis Lymphoma
This study was supported by research funding from AstraZeneca PLC to GGB, CQ, MT, AV, CC, PW, NL, SR, SW, OF, KA, LLG, XY, CW, RS, and DB.
- 7.Maloney DG, Smith B, Appelbaum FR (1996) The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes anti-proliferative activity and induction of apoptosis. Blood 88:637aGoogle Scholar
- 18.Umana P, Moessner E, Bruenker P et al (2006) Novel 3 rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. ASH Annual Meeting Abstracts 108:229Google Scholar
- 23.Polyak MJ, Deans JP (2002) Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 99:3256–3262CrossRefPubMedGoogle Scholar
- 30.Bertolini F, Fusetti L, Mancuso P, Gobbi A, Corsini C, Ferrucci PF, Martinelli G, Pruneri G (2000) Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 96:282–287PubMedGoogle Scholar
- 37.Bannerji R, Flinn I (2000) Cell surface complement inhibitors CD55 and CD59 may mediate chronic lymphocytic leukemia (CLL) resistance to rituximab therapy. Blood 96:164aGoogle Scholar